| Title: | Association of gene variant type and location with breast cancer risk in the general population |
| Journal: | Annals of Oncology |
| Published: | 25 Apr 2025 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/40288678/ |
| DOI: | https://doi.org/10.1016/j.annonc.2025.04.010 |
| URL: | https://www.ncbi.nlm.nih.gov/pmc/articles/12288856 |
Publication 15798
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BACKGROUND: Pathogenic variants (PVs) in ATM, BRCA1, BRCA2, CHEK2, and PALB2 are associated with increased breast cancer risk. It is unknown, however, whether this risk differs by PV type or location in carriers ascertained from the general population.</p>
PATIENTS AND METHODS: To evaluate breast cancer risks associated with PV type and location in ATM, BRCA1, BRCA2, CHEK2, and PALB2, we carried out age-adjusted case-control association analysis in 32 247 women with and 32 544 age-matched women without breast cancer from the CARRIERS Consortium. PVs were grouped by type and location within genes and assessed for risks of breast cancer [odds ratios (OR), 95% confidence intervals (CI), and P values] using logistic regression.</p>
RESULTS: Compared with women carrying BRCA2 exon 11 protein truncating variants (PTVs) in the CARRIERS population-based study, women with BRCA2 ex1-10 PTVs (OR = 13.5, 95% CI 6.0-38.7, P < 0.001) and ex13-27 PTVs (OR = 9.0, 95% CI 4.9-18.5, P < 0.001) had higher breast cancer risks, lower rates of estrogen receptor (ER)-negative breast cancer (ex13-27 OR = 0.5, 95% CI 0.2-0.9, P = 0.035; ex1-10 OR = 0.5, 95% CI 0.1-1.0, P = 0.065), and earlier age at breast cancer diagnosis (ex13-27 5.5 years, P < 0.001; ex1-10 2.4 years, P = 0.169). These associations with ER-negative breast cancer and age were replicated in a high-risk clinical cohort from Ambry Genetics and the population-based UK Biobank cohort. No differences in risk by gene region were observed for PTVs in other predisposition genes.</p>
CONCLUSIONS: Population-based and clinical high-risk cohorts establish that PTVs in exon 11 of BRCA2 are associated with reduced breast cancer risk, later age at diagnosis, and greater risk of ER-negative disease. These differential risks may improve individualized risk prediction and clinical management for women carrying BRCA2 PTVs.</p>
14 Keywords
- Adult
- Aged
- Ataxia Telangiectasia Mutated Proteins
- BRCA1 Protein
- BRCA2 Protein
- Breast Neoplasms
- Case-Control Studies
- Checkpoint Kinase 2
- Fanconi Anemia Complementation Group N Protein
- Female
- Genetic Predisposition to Disease
- Humans
- Middle Aged
- Risk Factors
45 Authors
- M.P. Akamandisa
- N.J. Boddicker
- S. Yadav
- C. Hu
- S.N. Hart
- C.B. Ambrosone
- H. Anton-Culver
- P.L. Auer
- C. Bodelon
- E.S. Burnside
- F. Chen
- A.H. Eliassen
- D.E. Goldgar
- C. Haiman
- J.M. Hodge
- H. Huang
- E.M. John
- R. Karam
- J.V. Lacey
- S. Lindstroem
- M.E. Martinez
- J. Na
- S.L. Neuhausen
- K.M. O'Brien
- J.E. Olson
- T. Pal
- J.R. Palmer
- A.V. Patel
- T. Pesaran
- E.C. Polley
- M.E. Richardson
- K.J. Ruddy
- D.P. Sandler
- L.R. Teras
- A. Trentham-Dietz
- C.M. Vachon
- C. Weinberg
- S.J. Winham
- S. Yao
- G. Zirpoli
- P. Kraft
- J.N. Weitzel
- S.M. Domchek
- F.J. Couch
- K.L. Nathanson
Enabling scientific discoveries that improve human health